Research

Malaria booster vaccine shows durable high efficacy in African children, meeting WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ - which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

Strict COVID lockdowns in France improved cardiovascular health

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measurable impact on vascular health. The study compared the impact on the health of people living in a partial vs. a total lockdown during the beginning of COVID-19.

Stem cell-gene therapy shows promise in ALS safety trial

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig's disease.

Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imdevimab) for the treatment of mild to moderate COVID-19 in high-risk, non-hospitalized patients.

Efficacy, cash and more will increase booster shot acceptance

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with cash incentives and if it is made by Moderna or Pfizer.

As the Omicron variant of COVID-19 emerged, Cornell researchers conducted the public opinion survey - thought to be one of the first to assess the factors that affect people's willingness to receive a vaccine booster.

New generation of corona vaccine shows promising results

Researchers at Karolinska Institutet in Sweden are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans.

Study first to link weed killer Roundup® to convulsions in animals

A recent report by the United States Centers for Disease Control and Prevention found more than 80 percent of urine samples from children and adults in the U.S. contained the herbicide glyphosate. A study by Florida Atlantic University and Nova Southeastern University takes this research one step further and is the first to link the use of the herbicide Roundup®, a widely used weed killer, to convulsions in animals.

Malaria booster vaccine shows durable high efficacy in African children, meeting WHO-specified 75% efficacy goal

Strict COVID lockdowns in France improved cardiovascular health

Stem cell-gene therapy shows promise in ALS safety trial

Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use

Efficacy, cash and more will increase booster shot acceptance

New generation of corona vaccine shows promising results

Study first to link weed killer Roundup® to convulsions in animals

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs